Browse Companies

Inhibrx Biosciences, spun off in 2024 from Inhibrx, Inc., develops novel multivalent biologic therapies targeting oncology indications. Its lead clinical programs, ozekibart (INBRX-109) and INBRX-106, employ proprietary modular protein engineering platforms designed for optimized agonist function. While early revenue increased to $1.3 million in 2025, the company remains unprofitable with operating losses narrowing to $135 million. Cash reserves of $124 million provide runway amid a $175 million secured loan subject to restrictive covenants. Management is exploring strategic alternatives for ozekibart monetization, underscoring both growth potential and execution risks. The firm faces typical biotech challenges including regulatory uncertainty, competitive pressures, and the need to build commercialization capabilities.

Sky Harbour Group Corp has rapidly expanded its footprint in the niche market of business aircraft hangar infrastructure, capitalizing on a structural shortage of suitably sized hangars driven by the growth of large private jets with taller tail heights and winglets. Despite strong top-line growth reaching $27.54 million in 2025, operating losses remain elevated due to aggressive capital expenditures required for development of new HBO campuses. The company maintains a diversified tenant base with long-term leases providing steady revenue visibility but faces liquidity and execution risks given its dependence on bond financing and bank debt. Monitoring project completions, occupancy stabilization near current ~78%, and capital market conditions will be critical to assess Sky Harbour's path toward positive operating cash flow and sustainable returns.

Solid Biosciences Inc. continues to push forward with its gene therapy efforts for rare neuromuscular diseases, highlighted by dosing the first patient in the Phase 3 IMPACT DUCHENNE trial. Despite clinical momentum, the company faces steep financial challenges, marked by mounting net losses and heavy cash burn reflective of intensive R&D spending. The firm's strong cash position supports ongoing operations but signals dependency on future capital raises to sustain pipeline advancement and eventual commercialization. Regulatory complexities, orphan drug advantages, and potential partnership needs underscore the multifaceted landscape shaping Solid’s near-term outlook.

Mustang Bio, a clinical-stage biopharmaceutical firm, focuses on licensed immunotherapies targeting difficult solid tumors with CAR T-cell (MB-101) and oncolytic virus (MB-108) programs. Despite accumulated losses nearing $398.6 million and ongoing negative cash flow of $5.26 million in 2025, the company has bolstered liquidity through equity offerings and warrant exercises to extend its runway. Regulatory dynamics, including FDA orphan drug designations and review of MB-109 combination therapy, present critical inflection points. Mustang faces capital constraints, regulatory complexities, and reliance on exclusive licensing partnerships, shaping a high-risk developmental trajectory.

ACCESS Newswire Inc.’s latest quarterly filing reveals a strategic pivot emphasizing its ACCESSWIRE brand and sister platforms after selling its Compliance segment in early 2025. This communications-centric business model relies heavily on subscription revenues supported by robust technology and key distribution partnerships. Competitive pressure from larger incumbents tempers pricing power, but the company’s integrated platform and partner relationships provide defensive moats. Growth drivers hinge on product innovation, expanding customer adoption, and maintaining strong partner integrations. Key risks include intense competition, reliance on technology infrastructure, and ongoing indemnification disputes related to the Compliance sale.

Tigo Energy, Inc. executed a notable financial rebound in 2025 with revenue nearly doubling to $103.5 million from the prior year’s $54.0 million, marking a sharp recovery from steep losses experienced in 2024. This upswing was driven by strong demand for its Module Level Power Electronics (MLPE) and energy storage systems across diverse geographies, notably EMEA and the Americas. The company’s contract manufacturing model and focus on R&D underpin ongoing innovation in both hardware and SaaS offerings such as Predict+. While improving operational efficiency narrowed its operating loss considerably, tariff exposure and concentrated supply chains remain key risks. Future growth depends on continued geographic expansion, new product introductions, and navigating regulatory headwinds.

Zion Oil & Gas has focused for over 25 years on onshore oil and gas exploration in Israel, operating under exclusive licenses granted by the Israeli government. The company holds extensive acreage but currently generates no revenue, relying heavily on equity sales to fund costly exploration programs. Recent recompletion efforts at its MJ-01 and MJ-02 wells have shown promising gas flows, yet commercial viability remains uncertain. Zion contends with complex regulatory landscapes, visa constraints, and geopolitical risks that could delay operations and inflate costs. Its financials reveal sustained net losses, negative operating cash flow, and substantial capital requirements ahead. The company’s future growth depends critically on successful drilling outcomes and continued access to capital.

electroCore, Inc. has transitioned from a focus on prescription bioelectronic therapies toward expanding its portfolio of general wellness and human performance products, aiming to diversify revenue beyond heavily concentrated government healthcare contracts. Despite ongoing operating losses and liquidity challenges, the company is investing in commercial infrastructure and direct-to-consumer sales channels to drive growth. A patent infringement lawsuit with UAB Pulsetto poses legal uncertainty and potential financial burden. Regulatory complexities and reimbursement hurdles further complicate market penetration, underscoring risks tied to supplier single sourcing and payor coverage. Monitoring developments in litigation outcomes, market acceptance of new wellness offerings, and execution of commercialization strategies will be critical in 2026.

Galecto, Inc. has entered a transitional phase marked by a transformative merger, strategic focus on oncology and rare diseases, and an ample capital infusion via a $275 million public offering. The company’s recent financials reveal sharply increased operating losses driven by expanded clinical activity, balanced by a robust liquidity position that supports ongoing development. Milestones in clinical trials and regulatory approvals remain pivotal for Galecto’s trajectory as it navigates inherent biotech risks amidst market skepticism.

SELLAS Life Sciences Group focuses exclusively on clinical-stage cancer therapies, including licensed assets SLS009 and GPS. Despite ongoing net losses and negative operating cash flow reflecting its pre-commercial status, the company maintains a strong liquidity position with $71.8 million cash at end-2025 plus additional warrant exercise proceeds post-year-end. Future growth hinges on clinical trial success, regulatory approvals, partnerships, and further financing to sustain operations amid high development costs.

United States Antimony Corp (UAMY) is the only vertically integrated and permitted domestic processor of antimony in the U.S., supported by significant multi-year contracts including a $248 million IDIQ with the U.S. Defense Logistics Agency. Since 2024, it expanded mining claims across North America and tripled processing capacity in Montana, driving a revenue surge in 2025 despite operating losses from aggressive capital investments. Government funding under Title III of the Defense Production Act supports modernization initiatives. Upcoming milestones include scaling production to meet contract demand and managing supply chain risks.

In the first quarter of 2026, Terra Property Trust executed an exchange offer for its maturing senior notes, aiming to optimize its debt profile and enhance capital flexibility. The firm’s business model centers on originating and managing $10 million to $50 million middle-market commercial real estate loans across diverse property types and geographies. Terra leverages Terra Capital Partners’ underwriting expertise and external management to sustain a niche competitive advantage. Key growth drivers include origination capabilities and loan structuring flexibility, balanced against risks from credit exposure and near-term refinancing demands. Monitoring debt maturities, liquidity positions, and distribution policies will be critical in assessing Terra’s operational stability and growth trajectory.

Alumis Inc. demonstrated a significant clinical milestone in early 2026 with positive Phase 3 topline results for its lead TYK2 inhibitor, envudeucitinib, targeting moderate-to-severe plaque psoriasis. This breakthrough underpins the company’s transition from clinical development to commercial readiness, supported by ongoing Phase 2 studies and an expanding pipeline including CNS-penetrant compounds and acquired monoclonal antibody assets. Despite considerable operating losses intensifying year-over-year due to R&D investments, Alumis sustains a strong liquidity position and strategic capital allocation to support next-stage growth, although manufacturing dependencies on third-party suppliers introduce operational risks ahead of product launch.

SailPoint, Inc. has grown rapidly, nearly doubling revenue from $699.6 million to $1.1 billion over two years by expanding its AI-powered Identity Security Cloud. The company’s future growth hinges on broadening its large global customer base, enhancing solutions for machine and AI identities, and deepening partnerships across geographies. However, SailPoint faces operational risks related to scaling, acquisition integration, evolving regulations especially around AI compliance, and intense market competition. Despite negative operating income recently reported at roughly $307 million, the firm maintains a solid balance sheet with $358 million in cash and positive free cash flow, underpinning ongoing R&D investments.

In its first quarter ended May 2, 2026, Five Below demonstrated sustained momentum through a meaningful increase in comparable store sales and accelerated new store openings, moving closer to its target of over 3,500 locations. This operational performance validates the company’s proven store economics and dynamic merchandising approach, which resonates strongly with its younger, value-seeking customer base. Challenges around inflation and supply chain complexities persist but have been largely mitigated through disciplined pricing strategies and logistical investments, supporting Five Below’s expanding footprint and solid cash flow generation.

Westwater Resources, Inc. is an energy technology company focused on producing battery-grade natural graphite materials using patented environmentally friendly purification processes. The company’s Kellyton Graphite Plant in Alabama is under construction, aiming to supply lithium-ion battery manufacturers with its ULTRA-CSPG™ products. Despite advances in plant construction and patent issuance in 2025, the unexpected termination of a key FCA offtake agreement has paused planned debt syndication efforts, compelling Westwater to rely on equity financings and explore government-backed funding alternatives. As a development-stage entity, the company continues to post net losses and negative cash flows while strategically managing capital raising and operational readiness for commercial production.

MultiSensor AI Holdings, Inc. has demonstrated steady progress in refining its financial profile despite ongoing losses as it transitions from a transactional hardware vendor to a software-centric predictive maintenance provider. The firm leverages its proprietary MSAI Connect platform to unify diverse sensor data streams, targeting automation-intensive markets such as distribution, manufacturing, and data centers. With expansion focused on increasing software attachment rates and recurring revenue, the company faces execution risks but is supported by a robust technology moat and a significant total addressable market estimated at $9 billion in 2025.

Gambling.com Group Ltd experienced robust revenue growth of 30% in 2025, driven by strategic acquisitions and expanding subscription services. Despite top-line gains, profitability pressures emerged from increased operating expenses and declining organic customer acquisition tied to Google algorithm changes. The company’s strong brand assets and technology platform underpin its competitive moat but its returns declined amidst rising regulatory uncertainties and dependency on search visibility. Capital structure enhancements, including a $165 million syndicated credit facility, provide flexibility to support operations and acquisitions. Key metrics to watch include organic customer trends, operating leverage realization, and covenant adherence amid market variability.

CSLM Digital Asset Acquisition Corp III, Ltd (KOYN) is a Cayman Islands-incorporated blank check company formed in July 2024 targeting digital asset infrastructure and blockchain-related businesses primarily in emerging and frontier markets. It raised gross proceeds of $230 million in its August 2025 IPO plus an additional $8.9 million via private placement, with funds held in trust for a future business combination. The company has no operating revenues to date but recorded net income driven by trust account interest; operational expenses reflect typical organizational costs. Success hinges on completing a quality initial business combination within the mandated timeframe, leveraging management's experience and network to access underpenetrated markets characterized by scalable platforms and ESG-focused companies. Capital allocation remains conservative pre-combination with no dividends or buybacks planned, while governance structures provide sponsor alignment but potential dilution risks persist. Market watchers should monitor deal announcements and shareholder voting events as catalysts.

Odysight.ai Inc. leverages miniature vision sensors combined with AI/ML algorithms to address predictive maintenance in inaccessible, high-risk environments, mainly in aerospace and industrial sectors. The company has secured key defense and aerospace customers and progressed from trials to commercial rollouts but remains unprofitable with widening operating losses and negative operating cash flow as of 2025 [F1][S1][S4]. Growth is driven by expanding aerospace contracts and emerging Industry 4.0 applications, while long sales cycles, geopolitical risks, and tariff-induced supply chain pressures cloud near-term revenue visibility [S1][S21][S4]. Continued R&D investment aims to sustain technological leadership; capital allocation focuses on growth without dividends or buybacks [F1][S25].

In the latest quarter, NovaBay Pharmaceuticals executed a fundamental strategic pivot, legally changing its name to Stablecoin Development Corporation and transitioning towards a blockchain-centric business model. It now holds approximately 2.15 billion SKY tokens engaged in on-chain staking activities, generating staking rewards that represent the company’s new revenue stream. This move away from pharmaceuticals positions it within the emerging digital asset ecosystem but accompanies notable financial reporting complexities and regulatory risks. Key growth drivers include management alignment via new equity incentives and expanding token holdings, while close monitoring of accounting restatements and market dynamics remains essential.

Eledon Pharmaceuticals is a clinical-stage biotech focused on therapies to prevent organ transplant rejection, with no commercial products. Its lead candidate, tegoprubart, recently received FDA orphan drug designation for liver transplantation, enhancing regulatory positioning. The company continues to incur significant operating losses driven by clinical development and finances operations primarily through equity raises, maintaining a solid liquidity buffer but negative free cash flow. Future growth depends heavily on successful clinical milestones, regulatory approvals, and strategic capital allocation amid inherent clinical-stage risks.

Avalon Holdings Corp’s Q1 2026 report reveals continued strength in its golf and related operations segment, which benefits from deferred membership dues and a no-initiation-fee structure that supports stable revenue recognition. Meanwhile, the company’s waste management services remain highly competitive and face pressure due to customer concentration and fragmented market dynamics. Avalon maintains compliance with debt covenants under its 2022 Term Loan and holds moderate liquidity as of March 31, 2026. The dual-segment business model provides diversification but also requires balancing operational complexities between recreation/hospitality and specialized environmental services.

Bakkt, Inc. released its Q1 2026 results emphasizing the strategic pivot toward stablecoin-based payments through the acquisition of Distributed Technologies Research Global Ltd. (DTR). This shift underpins a broader transformation from traditional digital asset brokerage to an institutional-grade, compliant infrastructure platform. However, integration of DTR’s nascent technology presents operational and regulatory risks that could affect growth trajectories and profitability. Bakkt’s regulatory licenses and legacy infrastructure provide a moat, but execution on the DTR platform and evolving multi-jurisdictional regulations remain key watchpoints.

Founded in early 2024, Columbus Acquisition Corp operates as a blank check company with no operating revenues to date, having raised $60 million in its January 2025 IPO. Its financial performance reflects typical SPAC startup costs with no revenues and losses from operating expenses. The company’s immediate future depends critically on completing a business combination with WISeSat.Space Holdings Corp by the extended deadline in January 2027, while managing tight liquidity and capital allocation to cover transaction-related costs. Investor protections include a trust account holding IPO proceeds and required shareholder approvals of the business combination. Although net income reported for FY2025 is positive due to non-operating factors, ongoing cash outflows from operations highlight funding challenges prior to deal consummation.

Netcapital Inc. has experienced a pronounced collapse in revenue over the past two years, driven by shifts in its funding portal business and intensifying regulatory costs. Operating losses have deepened significantly, while liquidity constraints and doubtful going concern status spotlight the firm’s financial fragility. The company is attempting a strategic pivot towards broker-dealer services targeting Regulation A and D offerings alongside acquisitions in blockchain cybersecurity, yet faces concentrated client risk and ongoing SEC investigations. Critical upcoming regulatory milestones and liquidity improvements will determine whether this transition stabilizes or further pressures capital preservation.

Strive, Inc., the first U.S. publicly traded bitcoin treasury asset manager, reported in its latest quarter notable private exchanges of convertible notes for SATA Stock and steady operational positioning. The company maintains over $2.4 billion in AUM anchored by a bitcoin hurdle rate strategy and innovative perpetual preferred equity known as SATA Stock, enabling flexible capital formation. Recent developments include acquisition integration risks from Semler Scientific's healthcare business and continuing regulatory challenges, while Strive aims to balance growth in bitcoin reserves with discipline amid inherent market volatility.

Strawberry Fields REIT, Inc. has recorded robust growth in operating income and net income, supported by its focus on triple-net leased skilled nursing and healthcare facilities across multiple states. This niche specialization underpins stable rental revenues amid a complex regulatory landscape. The company’s capital structure features a diversified bond and senior debt mix with prudent liquidity management. Dividend payments align with cash flow strength, while share repurchases remain modest. Future growth depends on tenant credit quality, geographic expansion, and regulatory developments impacting lease renewals and acquisition strategies.

SilverBox Corp IV (SBXD) functions primarily as a Special Purpose Acquisition Company aiming to merge with Parataxis Holdings, an institutional bitcoin-native digital asset manager focused on South Korea. The emerging combined entity emphasizes bitcoin treasury, mining operations, and expansion into Ethereum-related services. Despite reporting net income growth in its latest fiscal year, SilverBox faces limited liquidity and a negative equity position, reflecting typical SPAC-stage financials. Completion of the business combination and effective execution in the volatile digital asset sector will be key drivers of future performance, with risks tied to regulatory developments, shareholder redemptions, and operational scaling challenges.

Almaden Minerals Ltd, a Canadian mineral exploration entity, has faced significant setbacks following the retroactive termination of its Tuligtic Project concessions in Mexico. Without mining revenues, its recent financial performance reflects gains from asset sales and steady income from administrative service agreements with subsidiaries. The company's future hinges heavily on ongoing international arbitration against Mexico under the CPTPP framework seeking over US$1 billion in damages. Regulatory uncertainty in Mexico continues to pose risks, while Almaden maintains sufficient liquidity to operate through litigation phases and corporate developments.

Netlist Inc grew revenue substantially from 2014 through 2017 but has since experienced sustained operating and net losses through 2025. The company focuses on cutting-edge memory subsystems and Compute Express Link (CXL) technology, targeting OEMs in server, HPC, and cloud markets. Despite technological innovation and a strong patent portfolio, Netlist’s financial performance shows negative cash flow and equity erosion. Its business model relies heavily on reselling SK hynix components and sales to a concentrated customer base. Liquidity is supported by recent equity raises and a revolving credit facility, with management confident of funding for at least the next 12 months. Risks include ongoing patent litigation, supplier dependency post-2026 contract expiration, and lack of long-term customer agreements.

Coeptis Therapeutics Holdings, Inc. completed a significant business combination with Z Squared, Inc. in April 2026, repositioning itself as an altcoin-focused digital asset miner through its subsidiary OpCo. Operating a fleet of specialized ASIC miners across six North American sites, the company emphasizes operational efficiency and dynamic fleet management tailored to Dogecoin and Litecoin mining. Despite early-stage operational status and capital-intensive asset procurement, Coeptis faces liquidity risks but plans to expand via additional equity financing and strategic infrastructure acquisitions such as Skycore Digital LLC. The company’s deep sector expertise and service agreements underpin its competitive niche within the evolving cryptocurrency mining ecosystem.

In 2025, Camtek Ltd achieved a milestone revenue of $496 million, fueled by strong demand for inspection and metrology systems tailored to advanced semiconductor packaging for AI applications such as High Bandwidth Memory and silicon carbide devices. Despite a substantial drop in GAAP net income primarily due to convertible note repurchases, operating income rose robustly, reflecting operational scale and improved gross margins. The company faces risks related to long sales cycles and geographic concentration in the Asia Pacific region but benefits from strategic partnerships and acquisitions that bolster its technology moat. Management forecasts sustained double-digit revenue growth in 2026 supported by meaningful order backlog from IDM customers.

Since its incorporation in 2020, BullFrog AI Holdings, Inc. has advanced its bfLEAP™ platform to tackle complex biomedical data and drug repositioning, showing nearly 80% annual revenue growth from 2022 through 2025. Despite technological strides and strategic collaborations to leverage failed late-stage drug candidates, the company continues to report substantial operating losses and negative cash flows. BullFrog's limited cash reserves and Nasdaq listing compliance challenges highlight liquidity risks that constrain its runway and underline the critical need for additional funding. Regulatory requirements and competitive dynamics further complicate the roadmap ahead for this emerging digital biopharmaceutical firm.

Red Cat Holdings Inc operates in the defense technology sector, focusing on tactical unmanned aerial and surface systems. The company has experienced a steep decline in revenue alongside escalating operating losses in recent years, influenced by competitive pressures and supply chain constraints. While Red Cat maintains strategic partnerships and a foothold in U.S. defense contracts, persistent financial deficits and regulatory complexities temper its near-term outlook.

NuCana plc remains a clinical-stage player specializing in oncology therapeutics, with its pipeline centered on NUC-7738 and NUC-3373. The company posted a substantial net loss of £29.4 million in 2025, worsening from prior years, while maintaining a healthy cash position of £24.3 million at year-end. Its value proposition hinges on proprietary drug candidates protected by issued patents, with key development milestones expected from ongoing trials in PD-1 inhibitor-resistant melanoma and other indications. Capital structure improvements and leadership appointments seek to stabilize operations amid the uncertainty typical for pre-commercial biopharmaceutical companies.